The global sepsis diagnostics market was estimated at USD 448.35 Million in 2017 and is anticipated to gain significant traction over coming years. Sepsis is a critical complication rising owing to a cooperated immune system that leads individuals to become susceptible to fungal, parasitic, viral, bacterial or other infections. Sepsis is the most common reasons for the death in hospitals. Sepsis arises when the host immune system responds to any infection. The chemicals are released by the immune system to extravagance the infection. Upon entering the bloodstream, the infection causes inflammation all over the body. this leads to poor blood flow, blood clots, and leakage in blood vessels moreover, it divests the vital organs of the body of nutrients and oxygen. Sepsis is deliberated as a three-staged disorder by many physicians starting with sepsis, leading to severe sepsis, and as a final point septic shock, which is deliberated as a medical emergency. Geriatric population, people with chronic diseases such as AIDA, diabetes, and cancer, children and people with a weak immune system, children are amongst high risk of getting sepsis.
The present approaches of sepsis diagnostics depend on non-specific clinical and physiological standards, which may make it difficult to distinguish sepsis from a systematic inflammatory response triggered by normal inflammation. The blood test is the initial test to ratify the infection, impaired oxygen availability, and clotting. Other laboratory tests include wound secretions, respiratory, and urine secretion tests. If the validation of sepsis, as well as the source of inflammation, is not found then Ultrasound, Magnetic Resonance Imaging (MRI), X-rays, and Computerized Tomography (CT) scanning are used.
The global sepsis diagnostics market is majorly driven by factors such as geriatric population, increasing occurrence of different antibiotic-resistant bacterial strains, and, growing healthcare awareness and health care spending. Additionally, increasing number of surgical processes and rise in the number of product approvals for sepsis diagnosis are anticipated to enhance the global sepsis market during the forecast period. The high occurrence of Hospital Acquired Infection (HAI) is another major factor boosting the growth of the global sepsis diagnostics market. For instance, according to the Centers for Disease Control and Prevention (CDC) 2011, around 1.7 million HAIs from all types of bacteria combined are reported every year in the U.S. Additionally, according to the ECDC report, around 4.1 million patients were diagnosed with HAI in Europe in 2013. Thus rising prevalence demanding better diagnosis and treatments are anticipated top bolster the global sepsis diagnostics market during the forecast period. However, lack of standard protocols and a shortage of skilled staff in developing countries is hampering the growth of the sepsis diagnostics market.
The global Sepsis Diagnostics Market Size is segmented on the basis of products, technology, pathogen, testing type, and geography.
On the basis of products, the global Sepsis Diagnostics Market Size is segmented into Instruments, Blood Culture Media, and Assay Kits and Reagents. In 2017, the blood culture media was projected to be the major market sharing segment during the forecast period. The cost-effectiveness mode of the test is the primary reason for the major market share. In addition, due to the lower cost, the blood culture method is also considered as the gold standard method. On the basis of technology, the global sepsis diagnostics market is segmented into Microbiology, Molecular Diagnostics, Immunoassays, and Flow Cytometry. The microbiology segment was estimated to be the dominating segment due to the fact that it permits the identification and quantitative detection of microbes for sepsis diagnosis through the application of culture media tests. On the basis of the pathogen, the global sepsis diagnostics market is segmented into Bacterial Sepsis and Fungal Sepsis. The bacterial sepsis id further categorized into, gram-positive bacteria and gram-negative bacteria. In 2017, the bacterial sepsis segment is anticipated to dominate the segment. This is due to the patients suffering from the blood poisoning disease is a generally considered as a casualty of bacterial infection. On the basis of test type, the global sepsis diagnostics market is segmented into Laboratory Testing and PoC Testing. In 2017, the laboratory testing type is estimated to dominate the market.
In terms of geography, North America is estimated to dominate the global sepsis diagnostics market. The dominance is attributed to the presence of a well-established healthcare substructure and the rapid implementation of advanced products. Moreover, septic poisoning is a primary cause of death in the U.S., further accelerating the demand for diagnostic products. however, Asia Pacific is anticipated to unveil lucrative growth rate during the forecast period. This region delivers immense prospects for key players through the introduction of novel sepsis diagnostic assessments to decrease the increasing death cases amongst the population base. The Asia Pacific is expected to dominate the Sepsis Diagnostics Market during the forecast period.
Major firms are focusing on small firms with a working methodology of securing the end goal to manage position in the market and are associated with mergers and acquisitions, key joint efforts, and novel item advancement to pick up profit share in the business. Some major key players in global Sepsis Diagnostics Market includes Becton, Dickinson and Company, bioMérieux SA, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Cepheid Inc., Bruker Corporation, and Nanosphere, Inc. among others.